Evolus' Botox competitor is here. Will it dent Allergan's sales?

The moment Allergan's been dreading has arrived. Evolus has snagged an OK for its rival to Allergan’s lead moneymaker, Botox. And now, as Wells Fargo analyst David Maris put it in a note to clients, “the wait is on” to see what kind of damage it does to the blockbuster’s sales.